Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products

Publisher Name :
Date: 02-Mar-2017
No. of pages: 76

Summary

Fatty liver disease (FLD) comprises a spectrum of chronic liver disorders characterized by excessive lipid accumulation in the liver (steatosis), which may lead to inflammation (steatohepatitis) and fibrosis. It has the potential to progress to end-stage liver diseases such as cirrhosis, liver cancer and liver failure. It is also associated with numerous complications and co-morbidities, including cardiovascular and metabolic diseases. FLD can be divided into non-alcoholic FLD (NAFLD) and alcoholic FLD (AFLD), depending on the history of alcohol use. Both can also be divided into two subgroups: steatosis and steatohepatitis.

FLD is the most common chronic liver disease in the world, and its global prevalence has increased rapidly in the past several decades. The worldwide prevalence of FLD is estimated at 20-45% in the general population, 70% in diabetic patients, and 50-90% in obese people. There is a broad consensus to describe the condition as the hepatic manifestation of metabolic syndrome, and it is closely associated with obesity, diabetes and dyslipidemia. NAFLD has become the main driver of the rapid growth of FLD prevalence, mainly due to the rising prevalence of obesity.

The FLD pipeline is relatively large, with 173 products in active development, which constitutes almost one fifth of the pipeline for the gastrointestinal therapy area. Many pipeline products for FLD are also in development for other non-hepatic fibrotic diseases or indications from the metabolic disorders therapy area - such as diabetes mellitus and dyslipidemia - reflecting the similarities in the underlying pathophysiology of these indications.

Strategic consolidation activity levels are relatively low in the FLD market, as reflected in the low number of licensing and co-development deals completed since 2006. Analysis of licensing and co-development deals relating to FLD therapeutics since 2006 has identified aggregate deal values of $778m and $1.8 billion, respectively.

Due to the increasing prevalence and the health burden of FLD, and the lack of therapeutic options, there is a high need to develop pharmacological strategies. This is especially the case for patients with steatohepatitis who are at the greatest risk of developing cirrhosis or liver cancer that can lead to liver failure. Due to the pathophysiological complexity of FLD and its diverse population, different therapeutic agents are likely to be needed in order to tackle the lipotoxic, inflammatory and fibrogenic effects seen in FLD.

The report “Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products” helps to understand the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options and algorithms.

In depth, this report provides the following analysis -


  • Provides the composition of the FLD market in terms of dominant classes of therapies. Key unmet needs are identified to allow a competitive understanding of gaps in the market.

  • Allows recognizing innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.

  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix tailored to FLD, all first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.


Companies mentioned in this report: Novartis, Celgene, NGM Biopharmaceuticals, Raptor Pharmaceuticals, chemomAb, Conatus Pharmaceuticals, BLR Bio.

Scope

FLD comprises a diverse patient population with significant unmet needs


  • What is the pathophysiology of FLD?

  • What are the common co-morbidities and complications?

  • What are the most significant unmet needs within the market?


The FLD pipeline is relatively large and has a high degree of first-in-class innovation


  • Which molecule types and molecular targets are most prominent within the pipeline?

  • Which first-in-class targets are most promising?

  • How does the ratio of first-in-class targets to first-in-class products differ by stage of development and molecular target class?


The FLD deal landscape shows rising deal volumes and considerable investment opportunities


  • Do FLD products attract high deal values?

  • Which molecule types and molecular targets dominate the deals landscape?

  • Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?


Reasons to buy

This report will allow you to -


  • Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, and treatment options and algorithms.

  • Visualize the composition of the FLD market in terms of dominant classes of therapies. Key unmet needs are identified to allow a competitive understanding of gaps in the market.

  • Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.

  • Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix tailored to FLD, all first-in-class targets in the pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.

  • Consider first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Frontier Pharma: Fatty Liver Disease - High Degree of First-in-Class Innovation, Dominated by Nuclear Receptor-Targeting NASH Products

Table of Contents

1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Executive Summary 5
2.1 Urgent Unmet Need Driven By Rising Prevalence 5
2.2 High Degree of First-in-Class Innovation 5
2.3 Rising Deal Volumes and Considerable Investment Opportunities in First-in-Class Product Development 5

3 The Case for Innovation 6
3.1 Growing Opportunities for Biologic Products 7
3.2 Diversification of Molecular Targets 7
3.3 Innovative First-in-Class Development Remains Attractive 7
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained Innovation 8
3.6 GBI Research Report Guidance 8

4 Clinical and Commercial Landscape 10
4.1 Disease Overview 10
4.2 Disease Symptoms 11
4.3 Epidemiology 11
4.4 Etiology and Risk Factors 11
4.4.1 Environmental Factors 11
4.4.2 Host Factors 12
4.5 Pathophysiology 13
4.5.1 Steatosis 13
4.5.2 Hepatocellular Injury and Inflammation 14
4.5.3 Fibrosis 15
4.5.4 Conclusion 15
4.6 Co-morbidities and Complications 16
4.7 Diagnosis 16
4.7.1 Diagnosis of Fatty Liver Disease 16
4.7.2 Disease Prognosis 17
4.8 Treatment 17
4.8.1 Lifestyle Intervention 17
4.8.2 Pharmacological Treatment 18
4.8.3 Liver Transplantation 19

5 Assessment of Pipeline Product Innovation 20
5.1 Pipeline by Stage of Development, Molecule Type and Molecular Target 20
5.2 First-in-Class Programs Targeting Novel Molecular Targets 27
5.3 ASH 33
5.4 AFLD 33
5.5 Steatohepatitis (unspecified) 34
5.6 FLD (unspecified) 34
5.7 Table of All Pipeline Products 35

6 Signaling Network, Disease Causation and Innovation Alignment 40
6.1 Complexity of Signaling Networks in FLD 40
6.2 Signaling Pathways and First-in-Class Molecular Target Integration 40
6.3 First-in-Class Matrix Assessment 41

7 First-in-Class Target Evaluation 44
7.1 Pipeline Programs Targeting Connective Tissue Growth Factor 44
7.2 Pipeline Programs Targeting Sterol Regulatory Element-Binding Protein 1 and 2 45
7.3 Pipeline Programs Targeting Acetyl-CoA Carboxylase 1 and 2 48
7.4 Pipeline Programs Targeting Galectin 3 50
7.5 Pipeline Programs Targeting Cathepsin B 52
7.6 Pipeline Programs Targeting NACHT, KKR and PYD Domains-Containing Protein 3 53
7.7 Pipeline Programs Targeting P2Y Purinoceptor 13 55
7.8 Pipeline Programs Targeting Serpin H1 56
7.9 Conclusion 58

8 Strategic Consolidations 59
8.1 Industry-Wide First-in-Class Deals 59
8.2 Licensing Deals 60
8.2.1 Deals by Region, Value and Year 60
8.2.2 Deals by Stage of Development and Value 62
8.2.3 Deals by Molecule Type, Molecular Target and Value 62
8.2.4 List of Deals with Disclosed Deal Values 63
8.3 Codevelopment Deals 64
8.3.1 Deals by Region, Value and Year 64
8.3.2 Deals by Stage of Development and Value 65
8.3.3 Deals by Molecule Type, Molecular Target and Value 65
8.3.4 List of Deals with Disclosed Deal Values 66
8.4 First-in-Class Programs with and without Prior Involvement in Licensing and Co-development Deals 66

9 Appendix 69
9.1 References 69
9.2 Abbreviations 73
9.3 Research Methodology 74
9.3.1 Data integrity 75
9.3.2 Innovative and meaningful analytical techniques and frameworks: 75
9.3.3 Evidence based analysis and insight: 75
9.4 Secondary Research 75
9.4.1 Market Analysis 75
9.4.2 Pipeline Analysis 75
9.4.3 First-in-Class Matrix Assessment 75
9.4.4 First-in-Class Target Profiles 76
9.4.5 Licensing and Co-Development Deals 76
9.5 Contact Us 76
9.6 Disclaimer 76

List of Tables

Table 1: Fatty Liver Disease Therapeutics Market, Survival Rates of Simple Steatosis and NASH/ASH, 2017 17
Table 2: Fatty Liver Disease Therapeutics Market, Global, Key Features and Pipeline Activity of Connective Tissue Growth Factor, 2017 45
Table 3: Fatty Liver Disease Therapeutics Market, Global, Pipeline Programs Targeting Connective Tissue Growth Factor, 2017 45
Table 4: Fatty Liver Disease Therapeutics Market, Global, Key Features and Pipeline Activity of Sterol Regulatory Element-Binding Protein 1, 2017 46
Table 5: Fatty Liver Disease Therapeutics Market, Global, Key Features and Pipeline Activity of Sterol Regulatory Element-Binding Protein 2, 2017 47
Table 6: Fatty Liver Disease Therapeutics Market, Global, Pipeline Programs Targeting Sterol Regulatory Element-Binding Protein 1, 2017 47
Table 7: Fatty Liver Disease Therapeutics Market, Global, Pipeline Programs Targeting Sterol Regulatory Element-Binding Protein 2, 2017 48
Table 8: Fatty Liver Disease Therapeutics Market, Global, Key Features and Pipeline Activity of Acetyl-CoA Carboxylase 1, 2017 49
Table 9: Fatty Liver Disease Therapeutics Market, Global, Key Features and Pipeline Activity of Acetyl-CoA Carboxylase 2, 2017 50
Table 10: Fatty Liver Disease Therapeutics Market, Global, Pipeline Programs Targeting Acetyl-CoA Carboxylase 1 and 2, 2017 50
Table 11: Fatty Liver Disease Therapeutics Market, Global, Key Features and Pipeline Activity of Galectin 3, 2017 51
Table 12: Fatty Liver Disease Therapeutics Market, Global, Pipeline Programs Targeting Galectin 3, 2017 52
Table 13: Fatty Liver Disease Therapeutics Market, Global, Key Features and Pipeline Activity of Cathepsin B, 2017 53
Table 14: Fatty Liver Disease Therapeutics Market, Global, Pipeline Programs Targeting Cathepsin B, 2017 53
Table 15: Fatty Liver Disease Therapeutics Market, Global, Key Features and Pipeline Activity of NACHT, KKR and PYD Domains-Containing Protein 3 Receptor, 2017 54
Table 16: Fatty Liver Disease Therapeutics Market, Global, Pipeline Programs Targeting NACHT, KKR and PYD Domains-Containing Protein 3, 2017 55
Table 17: Fatty Liver Disease Therapeutics Market, Global, Key Features and Pipeline Activity of P2Y Purinoceptor 13, 2017 56
Table 18: Fatty Liver Disease Therapeutics Market, Global, Pipeline Programs Targeting P2Y Purinoceptor 13, 2017 56
Table 19: Fatty Liver Disease Therapeutics Market, Global, Key Features and Pipeline Activity of Serpin H1, 2017 57
Table 20: Fatty Liver Disease Therapeutics Market, Global, Pipeline Programs Targeting Serpin H1, 2017 57

List of Figures

Figure 1: Fatty Liver Disease Therapeutics Market, US, Innovation Trends in Product Approvals, Number of Product Approvals by FDA and Five-Year Moving Average of Product Approvals, 1987-2014 6
Figure 2: Fatty Liver Disease Therapeutics Market, Sales Performance of First-in-Class and Non-First-in-Class Products Post Marketing Approval ($m), 2006-2013 8
Figure 3: Fatty Liver Disease Therapeutics Market, Global, Overall Pharmaceutical Industry Pipeline by Therapy Area, 2017 20
Figure 4: Fatty Liver Disease Therapeutics Market, Global, Pipeline by Stage of Development and Molecule Type, 2017 21
Figure 5: Fatty Liver Disease Therapeutics Market, Global, Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease Pipeline by Stage of Development and Molecule Type, 2017 23
Figure 6: Fatty Liver Disease Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2017 25
Figure 7: Fatty Liver Disease Therapeutics Market, Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease, Global, Pipeline by Molecular Target and Stage of Development, 2017 26
Figure 8: Fatty Liver Disease Therapeutics Market, Global, Distribution of Pipeline First-in-Class and Non-First-in-Class Products by Stage of Development and Molecular Target, 2017 27
Figure 9: Fatty Liver Disease Therapeutics Market, Global, Non-Alcoholic Steatohepatitis and Non-Alcoholic Fatty Liver Disease, Distribution of Pipeline First-in-Class and Non-First-in-Class Products by Molecular Target, 2017 28
Figure 10: Fatty Liver Disease Therapeutics Market, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Stage of Development (%), 2017 29
Figure 11: Fatty Liver Disease Therapeutics Market, Global, Percentage Distribution of First-in-Class and Non-First-in-Class Pipeline Products by Molecular Target (%), 2017 30
Figure 12: Fatty Liver Disease Therapeutics Market, Global, Ratio of First-in-Class Products to First-in-Class Targets by Stage of Development, 2017 31
Figure 13: Fatty Liver Disease Therapeutics Market, Global, Ratio of First-in-Class Products to First-in-Class Targets by Molecular Target, 2017 32
Figure 14: Fatty Liver Disease Therapeutics Market, Alcoholic Steatohepatitis, Global, Pipeline Products, 2017 33
Figure 15: Fatty Liver Disease Therapeutics Market, Alcoholic Fatty Liver Disease, Global, Pipeline Products, 2017 33
Figure 16: Fatty Liver Disease Therapeutics Market, Steatohepatitis (Unspecified), Global, Pipeline Products, 2017 34
Figure 17: Fatty Liver Disease Therapeutics Market, Fatty Liver Disease (Unspecified), Global, Pipeline Products, 2017 34
Figure 18: Fatty Liver Disease Therapeutics Market, Global, Pipeline Products, 2017 (Part 1) 35
Figure 19: Fatty Liver Disease Therapeutics Market, Global, Pipeline Products, 2017 (Part 2) 36
Figure 20: Fatty Liver Disease Therapeutics Market, Global, Pipeline Products, 2017 (Part 3) 37
Figure 21: Fatty Liver Disease Therapeutics Market, Global, Pipeline Products, 2017 (Part 4) 38
Figure 22: Fatty Liver Disease Therapeutics Market, Global, Pipeline Products, 2017 (Part 5) 39
Figure 23: Fatty Liver Disease Therapeutics Market, Global, First-in-Class Matrix Assessment, 2017 (Part 1) 42
Figure 24: Fatty Liver Disease Therapeutics Market, Global, First-in-Class Matrix Assessment, 2017 (Part 2) 43
Figure 25: Fatty Liver Disease Therapeutics Market, Global, Industry-Wide Deals by Stage of Development and First-in-Class Status, 2006-2014 59
Figure 26: Fatty Liver Disease Therapeutics Market, Global, Industry-Wide Licensing Deals by Deal Value, Upfront Payment Value, Stage of Development and First-in-Class Status, 2006-2014 60
Figure 27: Fatty Liver Disease Therapeutics, Global, Licensing Deals by Region, Value and Year, 2006-2017 61
Figure 28: Fatty Liver Disease Therapeutics, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2017 62
Figure 29: Fatty Liver Disease Therapeutics, Global, Number and Aggregate Deal Value of Licensing Deals by Molecule Type, 2006-2017 62
Figure 30: Fatty Liver Disease Therapeutics, Global, Number and Aggregate Deal Value of Licensing Deals by Molecular Target, 2006-2017 63
Figure 31: Fatty Liver Disease Therapeutics, Global, Licensing Deals with Disclosed Deal Values, 2006-2017 63
Figure 32: Fatty Liver Disease Therapeutics, Global, Co-development Deals by Region, Value and Year, 2006-2017 64
Figure 33: Fatty Liver Disease Therapeutics, Global, Co-development Deals by Stage of Development, Deal Value and Upfront Payment Value, 2006-2017 65
Figure 34: Fatty Liver Disease Therapeutics, Global, Number and Aggregate Deal Value of Co-development Deals by Molecule Type, 2006-2017 65
Figure 35: Fatty Liver Disease Therapeutics, Global, Number of Co-development Deals by Molecular Target, 2006-2017 66
Figure 36: Fatty Liver Disease Therapeutics, Global, Co-development Deals with Disclosed Deal Values, 2006-2017 66
Figure 37: Fatty Liver Disease Therapeutics Market, Global, First-in-Class Pipeline Products with Prior Involvement in Licensing or Co-development Deals, 2017 67
Figure 38: Fatty Liver Disease Therapeutics Market, Global, First-in-Class Pipeline Products with No Disclosed Prior Involvement in Licensing or Co-development Deals, 2017 68

  • Global (United States, European Union and China) anti-HA Antibody Market Research Report 2019-2025
    Published: 23-Aug-2019        Price: US 3280 Onwards        Pages: 122
    Monoclonal Antibodies (IgMs) are antibodies that are made by identical immune cells, cloned from a single parent cell. They are therefore of constant structure and bind to the same foreign markers (called "antigens"). The technology behind the generation of monoclonal antibodies was discovered in 1972 by César Milstein and Georges Köhler - scientists at the Roche-funded Basel Institute for Immunology - who were later to win the Nobel Prize. Monoclonal antibodies revolutionized biological researc......
  • Global (United States, European Union and China) Antiemetic Drugs Market Research Report 2019-2025
    Published: 23-Aug-2019        Price: US 3280 Onwards        Pages: 122
    An antiemetic drug is a drug that is effective against vomiting and nausea. Antiemetics are typically used to treat motion sickness and the side effects of opioid analgesics, general anaesthetics, antipsychotic medication and chemotherapy directed against cancer. The adoption of inorganic growth strategies including M&As, partnerships, and regional acquisition, result in improved market penetration of the vendors. Technological advancements result in improvement and expansion of the produ......
  • Global (United States, European Union and China) Valacyclovir Oral Market Research Report 2019-2025
    Published: 23-Aug-2019        Price: US 3280 Onwards        Pages: 122
    Valacyclovir is used to treat herpes virus infections, including herpes labialis (also known as cold sores), herpes zoster (also known as shingles), and herpes simplex (also known as genital herpes) in adults. It is also used to treat chickenpox and cold sores in children. In 2019, the market size of Valacyclovir Oral is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase......
  • Global (United States, European Union and China) Prophy Paste Market Research Report 2019-2025
    Published: 23-Aug-2019        Price: US 3280 Onwards        Pages: 122
    Prophy pastes for oral health treatments designed to be effective and kind on natural teeth and restorations. In 2019, the market size of Prophy Paste is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast ......
  • Global (United States, European Union and China) Human Embryonic Stem Cells (HESC) Market Research Report 2019-2025
    Published: 23-Aug-2019        Price: US 3280 Onwards        Pages: 122
    Human embryonic stem cell: also known as a human pluripotent stem cell, one of the "cells that are self-replicating, are derived from human embryos or human fetal tissue, and are known to develop into cells and tissues of the three primary germ layers. In 2019, the market size of Human Embryonic Stem Cells (HESC) is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to x......
  • Global (United States, European Union and China) Heart Failure Therapeutics Market Research Report 2019-2025
    Published: 23-Aug-2019        Price: US 3280 Onwards        Pages: 122
    Heart failure (HF), often referred to as congestive heart failure (CHF), is when the heart is unable to pump sufficiently to maintain blood flow to meet the body's needs. Signs and symptoms commonly include shortness of breath, excessive tiredness, and leg swelling.The shortness of breath is usually worse with exercise, while lying down, and may wake the person at night.A limited ability to exercise is also a common feature. Chest pain, including angina, does not typically occur due to heart fai......
  • Global (United States, European Union and China) Cancer Janus Kinase Inhibitors Market Research Report 2019-2025
    Published: 23-Aug-2019        Price: US 3280 Onwards        Pages: 122
    Cancer Janus Kinase Inhibitors The conventional modes of cancer management including surgery, radiotherapy and chemotherapy were discarded as an aspirant for the future of cancer management long back ago. The arrival of modern cancer treatment modalities like immunotherapy and targeted therapy revolutionized the outlook of the future of cancer management. Amongst both of the modern therapies, targeted therapies have shown an impressive growth in a very short duration of time. The targeted......
  • Global (United States, European Union and China) Cancer Drug Therapy Market Research Report 2019-2025
    Published: 23-Aug-2019        Price: US 3280 Onwards        Pages: 121
    Kidney cancer or renal cancer is one of the ten most frequently diagnosed cancers, found mainly in people aged 60 or above. According to the estimates of the American Cancer Society (ACS), 61,560 new kidney cancer cases and 14,080 deaths would occur in 2015. Due to the increasing prevalence with no cure of this deadly disease, till date, there is an imminent need for effective kidney cancer drugs. The renal cancer drug therapy market has witnessed a dramatic change in its treatment ......
  • Global (United States, European Union and China) Valsartan-Hydrochlorothiazide Market Research Report 2019-2025
    Published: 23-Aug-2019        Price: US 3280 Onwards        Pages: 121
    This drug is used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. This product contains two medications: valsartan and hydrochlorothiazide. Valsartan is an angiotensin receptor blocker (ARB) and works by relaxing blood vessels so that blood can flow more easily. Hydrochlorothiazide is a "water pill" (diuretic) that causes you to make more urine, which helps your body get rid of extra salt and water. In 2019, the market ......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs